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Background: In the PLATINUM randomized controlled trial, the PROMUS Element Everolimus Eluting Stent (PtCr-EES) was non-inferior to the cobalt 
chromium PROMUS/XIENCE V EES (CoCr-EES) for the primary endpoint of 12-month target lesion failure (TLF), with comparable cumulative 2-year 
outcomes. However, significantly lower TLF and target lesion revascularization (TLR) rates were observed for the PtCr-EES between 1 and 2 years in a 
landmark analysis. Three-year outcomes have not yet been reported.
methods: Patients (N=1530) with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter ≥2.50 mm to ≤4.25 mm and length 
≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. Exclusion criteria included acute or recent myocardial infarction (MI), left ventricular 
ejection fraction <30%, left main or ostial location, bifurcation disease, chronic total occlusion, and target vessel thrombus. Routine angiographic 
follow-up was not performed.
results: Baseline demographics and patient medical history were well-matched between the randomized study groups. Unplanned (bailout) 
stenting was more frequent in the CoCr-EES group (9.8%) compared to the PtCr-EES group (5.9%; P=0.004), due primarily to an increased incidence 
of inadequate lesion coverage (3.4% versus 1.4%, P=0.01). Previously reported 2-year results demonstrated no significant differences between 
CoCr-EES and PtCr-EES in death (2.8% vs. 2.4% respectively; P=0.71), myocardial infarction (2.2% vs. 1.6%; P=0.54), TLR (4.0% vs. 2.4%; P=0.12), 
or definite/probable stent thrombosis (0.7% CoCr-EES, 0.5% PtCr-EES; P=0.99). TLR between 1 and 2 years was significantly lower in the PtCr-EES 
group (2.2% vs. 0.7%, hazard ratio 0.33 [0.12-0.90], P=0.02), as was TLF (3.0% vs. 1.2%, hazard ratio 0.44 [0.20-0.97], P=0.04). Three-year clinical 
follow-up is underway.
conclusions: Overall 2-year outcomes were not significantly different between PtCr-EES and CoCr-EES, although beyond 1 year a divergence 
in revascularization rates was noted favoring PtCr-EES. Three-year results will be presented for the first time at the ACC in March 2013 and will 
determine whether or not late events continue to favor PtCr-EES.
